Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer’s Disease
Felipe Salech(University of Chile), María Isabel Behrens(Universidad del Desarrollo)
Cited by 85
Related Papers
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase
|Nature Genetics|2006|1.2k
<i>ATP13A2</i> variants in early‐onset Parkinson's disease patients and controls
|Movement Disorders|2009|75
A call for clinical trial globalization in Alzheimer's disease and related dementia
|Alzheimer s & Dementia|2023|31
Structural inequality linked to brain volume and network dynamics in aging and dementia across the Americas
|Nature Aging|2024|31
The impact of SARS‐CoV‐2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
|Alzheimer s & Dementia Translational Research & Clinical Interventions|2020|29